{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:35:17Z","timestamp":1790184917433,"version":"4.1.0"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Spinocerebellar ataxia type 2 (SCA2) is a polyglutamine disorder, and variants in its disease protein Ataxin-2 act as modifiers in the progression of Amyotrophic Lateral Sclerosis. There are no reliable molecular biomarkers for SCA2. The aim of this study was to define novel molecular biomarker candidates for SCA2. Using cerebellar and cervicothoracic spinal cord RNA\/protein from\n                    <jats:italic>Atxn2<\/jats:italic>\n                    -CAG100-KnockIn (KIN) and wildtype mice, a multi-omics study was conducted based on the integration of global transcriptomic, proteomic, and phosphoproteomic data, followed by validation in mice and humans.  Venn diagram comparisons across all OMICS datasets indicated that only\n                    <jats:italic>Serpinb1a<\/jats:italic>\n                    -transcript, SERPINB1A-protein and -phosphopeptides were consistently downregulated at terminal stage in 14-month-old KIN mice. Expression studies in cerebellum and spinal cord from 10 weeks (pre-manifest), 6-month-old (early ataxic), and 14-month-old (late ataxic stage) mice confirmed this progressive decrease at mRNA and protein level. SERPINB1 plasma levels were significantly lower in early-stage SCA2 patients, and displayed a significant association with the CAG repeat length at expanded\n                    <jats:italic>ATXN2<\/jats:italic>\n                    alleles, the age at onset and INAS count. However, these human data from this SCA2 founder population were not robust, so reappraisal in large international studies and at later disease stages of SCA2 is needed. SERPINB1 was identified as novel candidate progression biomarker for SCA2 pathomechanisms.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-29070-7","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:36:19Z","timestamp":1764142579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multiomics approach identifies SERPINB1 as candidate biomarker for spinocerebellar ataxia type 2"],"prefix":"10.1038","volume":"15","author":[{"given":"Luis E.","family":"Almaguer-Mederos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Key","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesli-Ece","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Canet-Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"D\u00f6ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Meierhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Gispert-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Cuello-Almarales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Almaguer-Gotay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia M.","family":"Osorio-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Aguilera-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Medrano-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Auburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"3","key":"29070_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng1196-285","volume":"14","author":"G Imbert","year":"1996","unstructured":"Imbert, G. et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG\/glutamine repeats. Nat. Genet. 14 (3), 285\u2013291 (1996).","journal-title":"Nat. Genet."},{"issue":"3","key":"29070_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/ng1196-269","volume":"14","author":"SM Pulst","year":"1996","unstructured":"Pulst, S. M. et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat. Genet. 14 (3), 269\u2013276 (1996).","journal-title":"Nat. Genet."},{"issue":"3","key":"29070_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/ng1196-277","volume":"14","author":"K Sanpei","year":"1996","unstructured":"Sanpei, K. et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat. Genet. 14 (3), 277\u2013284 (1996).","journal-title":"Nat. Genet."},{"issue":"6","key":"29070_CR4","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/mds.28498","volume":"36","author":"LE Almaguer-Mederos","year":"2021","unstructured":"Almaguer-Mederos, L. E. et al. Body mass index is significantly associated with disease severity in spinocerebellar ataxia type 2 patients. Mov. Disord. 36 (6), 1372\u20131380 (2021).","journal-title":"Mov. Disord"},{"issue":"3","key":"29070_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1399-0004.2012.01902.x","volume":"83","author":"LE Almaguer-Mederos","year":"2013","unstructured":"Almaguer-Mederos, L. E. et al. Estimation of survival in spinocerebellar ataxia type 2 Cuban patients. Clin. Genet. 83 (3), 293\u2013294 (2013).","journal-title":"Clin. Genet."},{"issue":"9","key":"29070_CR6","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1212\/WNL.40.9.1369","volume":"40","author":"G Orozco Diaz","year":"1990","unstructured":"Orozco Diaz, G. et al. Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holgu\u00edn, Cuba. Neurology 40 (9), 1369\u20131375 (1990).","journal-title":"Neurology"},{"key":"29070_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pneurobio.2013.01.001","volume":"104","author":"U R\u00fcb","year":"2013","unstructured":"R\u00fcb, U. et al. Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Prog Neurobiol. 104, 38\u201366 (2013).","journal-title":"Prog Neurobiol."},{"issue":"3","key":"29070_CR8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/ene.14601","volume":"28","author":"L Yang","year":"2021","unstructured":"Yang, L. et al. Genetic profile and clinical characteristics of Chinese patients with spinocerebellar ataxia type 2: A multicenter experience over 10 years. Eur. J. Neurol. 28 (3), 955\u2013964 (2021).","journal-title":"Eur. J. Neurol."},{"issue":"7310","key":"29070_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature09320","volume":"466","author":"AC Elden","year":"2010","unstructured":"Elden, A. C. et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466 (7310), 1069\u20131075 (2010).","journal-title":"Nature"},{"issue":"8","key":"29070_CR10","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1093\/brain\/awac167","volume":"145","author":"JD Glass","year":"2022","unstructured":"Glass, J. D. et al. ATXN2 intermediate expansions in amyotrophic lateral sclerosis. Brain 145 (8), 2671\u20132676 (2022).","journal-title":"Brain"},{"issue":"1","key":"29070_CR11","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1212\/WNL.0000000000207367","volume":"101","author":"A Chi\u00f2","year":"2023","unstructured":"Chi\u00f2, A. et al. Association of copresence of pathogenic variants related to amyotrophic lateral sclerosis and prognosis. Neurology 101 (1), e83\u2013e93 (2023).","journal-title":"Neurology"},{"key":"29070_CR12","doi-asserted-by":"publisher","first-page":"231e7","DOI":"10.1016\/j.neurobiolaging.2018.09.009","volume":"73","author":"E Rubino","year":"2019","unstructured":"Rubino, E. et al. ATXN2 intermediate repeat expansions influence the clinical phenotype in frontotemporal dementia. Neurobiol. Aging. 73, 231e7\u2013231e9 (2019).","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"29070_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40478-018-0547-8","volume":"6","author":"C Fournier","year":"2018","unstructured":"Fournier, C. et al. Interrupted CAG expansions in ATXN2 gene expand the genetic spectrum of frontotemporal dementias. Acta Neuropathol. Commun. 6 (1), 41 (2018).","journal-title":"Acta Neuropathol. Commun."},{"issue":"16","key":"29070_CR14","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1093\/hmg\/ddr227","volume":"20","author":"OA Ross","year":"2011","unstructured":"Ross, O. A. et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum. Mol. Genet. 20 (16), 3207\u20133212 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"29070_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.parkreldis.2017.04.003","volume":"40","author":"YE Kim","year":"2017","unstructured":"Kim, Y. E. et al. SCA2 family presenting as typical parkinson\u2019s disease: 34 year follow up. Parkinsonism Relat. Disord. 40, 69\u201372 (2017).","journal-title":"Parkinsonism Relat. Disord"},{"issue":"1","key":"29070_CR16","doi-asserted-by":"publisher","first-page":"103536","DOI":"10.1016\/j.isci.2021.103536","volume":"25","author":"U Del Castillo","year":"2022","unstructured":"Del Castillo, U. et al. Ataxin-2 is essential for cytoskeletal dynamics and neurodevelopment in drosophila. iScience 25 (1), 103536 (2022).","journal-title":"iScience"},{"issue":"47","key":"29070_CR17","doi-asserted-by":"publisher","first-page":"15810","DOI":"10.1074\/jbc.RA120.013835","volume":"295","author":"H Inagaki","year":"2020","unstructured":"Inagaki, H. et al. Direct evidence that Ataxin-2 is a translational activator mediating cytoplasmic polyadenylation. J. Biol. Chem. 295 (47), 15810\u201315825 (2020).","journal-title":"J. Biol. Chem."},{"issue":"9","key":"29070_CR18","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.bbadis.2016.05.017","volume":"1862","author":"I Lastres-Becker","year":"2016","unstructured":"Lastres-Becker, I. et al. Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K\/mTOR and is induced by starvation. Biochim. Biophys. Acta. 1862 (9), 1558\u20131569 (2016).","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"29070_CR19","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1111\/febs.17081","volume":"291","author":"YJ Liu","year":"2024","unstructured":"Liu, Y. J. et al. Ataxin-2 sequesters raptor into aggregates and impairs cellular mTORC1 signaling. Febs j. 291 (8), 1795\u20131812 (2024).","journal-title":"Febs j."},{"issue":"10","key":"29070_CR20","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.cellsig.2008.05.018","volume":"20","author":"D Nonis","year":"2008","unstructured":"Nonis, D. et al. Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. Cell. Signal. 20 (10), 1725\u20131739 (2008).","journal-title":"Cell. Signal."},{"issue":"4","key":"29070_CR21","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1093\/genetics\/162.4.1687","volume":"162","author":"TF Satterfield","year":"2002","unstructured":"Satterfield, T. F., Jackson, S. M. & Pallanck, L. J. A drosophila homolog of the polyglutamine disease gene SCA2 is a dosage-sensitive regulator of actin filament formation. Genetics 162 (4), 1687\u20131702 (2002).","journal-title":"Genetics"},{"issue":"15","key":"29070_CR22","doi-asserted-by":"publisher","first-page":"9193","DOI":"10.1093\/nar\/gkae497","volume":"52","author":"R Yamagishi","year":"2024","unstructured":"Yamagishi, R. et al. Concerted action of ataxin-2 and PABPC1-bound mRNA poly(A) tail in the formation of stress granules. Nucleic Acids Res. 52 (15), 9193\u20139209 (2024).","journal-title":"Nucleic Acids Res."},{"key":"29070_CR23","doi-asserted-by":"crossref","unstructured":"Almaguer-Mederos, L. E. et al. Spinal cord phosphoproteome of SCA2 mouse model reveals alteration of ATXN2-N-term PRM-SH3-actin interactome and of autophagy. Mol. Cell. Proteom., : p. 101072. (2025).","DOI":"10.1016\/j.mcpro.2025.101072"},{"issue":"Pt 10","key":"29070_CR24","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1093\/brain\/awg234","volume":"126","author":"U R\u00fcb","year":"2003","unstructured":"R\u00fcb, U. et al. Thalamic involvement in a spinocerebellar ataxia type 2 (SCA2) and a spinocerebellar ataxia type 3 (SCA3) patient, and its clinical relevance. Brain 126 (Pt 10), 2257\u20132272 (2003).","journal-title":"Brain"},{"key":"29070_CR25","doi-asserted-by":"publisher","first-page":"104559","DOI":"10.1016\/j.nbd.2019.104559","volume":"132","author":"NE Sen","year":"2019","unstructured":"Sen, N. E. et al. Generation of an Atxn2-CAG100 knock-in mouse reveals N-acetylaspartate production deficit due to early Nat8l dysregulation. Neurobiol. Dis. 132, 104559 (2019).","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"29070_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s004010050989","volume":"97","author":"R Estrada","year":"1999","unstructured":"Estrada, R. et al. Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 autopsies. Acta Neuropathol. 97 (3), 306\u2013310 (1999).","journal-title":"Acta Neuropathol."},{"issue":"3","key":"29070_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/bpa.12412","volume":"27","author":"K Seidel","year":"2017","unstructured":"Seidel, K. et al. On the distribution of intranuclear and cytoplasmic aggregates in the brainstem of patients with spinocerebellar ataxia type 2 and 3. Brain Pathol. 27 (3), 345\u2013355 (2017).","journal-title":"Brain Pathol."},{"key":"29070_CR28","doi-asserted-by":"crossref","unstructured":"Sen, N. E. et al. In human and mouse Spino-Cerebellar Tissue, Ataxin-2 expansion affects Ceramide-Sphingomyelin metabolism. Int. J. Mol. Sci., 20(23). (2019).","DOI":"10.3390\/ijms20235854"},{"issue":"4","key":"29070_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s12311-020-01134-6","volume":"19","author":"LE Almaguer-Mederos","year":"2020","unstructured":"Almaguer-Mederos, L. E. et al. Testosterone levels are decreased and associated with disease duration in male spinocerebellar ataxia type 2 patients. Cerebellum 19 (4), 597\u2013604 (2020).","journal-title":"Cerebellum"},{"issue":"8","key":"29070_CR30","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1080\/1028415X.2021.1895479","volume":"25","author":"T Rodriguez-Grana","year":"2022","unstructured":"Rodriguez-Grana, T. et al. Weight loss is correlated with disease severity in spinocerebellar ataxia type 2: a cross-sectional cohort study. Nutr. Neurosci. 25 (8), 1747\u20131755 (2022).","journal-title":"Nutr. Neurosci."},{"issue":"16","key":"29070_CR31","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1212\/WNL.0b013e3182166e13","volume":"76","author":"J Sone","year":"2011","unstructured":"Sone, J. et al. Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease. Neurology 76 (16), 1372\u20131376 (2011).","journal-title":"Neurology"},{"key":"29070_CR32","doi-asserted-by":"crossref","unstructured":"Sen, N. E. et al. ATXN2 polyglutamine expansion impairs QKI-dependent alternative splicing and oligodendrocyte maintenance. BioRxiv, (2025).","DOI":"10.1101\/2025.08.08.669189"},{"issue":"8","key":"29070_CR33","doi-asserted-by":"publisher","first-page":"102228","DOI":"10.1016\/j.jbc.2022.102228","volume":"298","author":"DR Scoles","year":"2022","unstructured":"Scoles, D. R. et al. A quantitative high-throughput screen identifies compounds that lower expression of the SCA2-and ALS-associated gene ATXN2. J. Biol. Chem. 298 (8), 102228 (2022).","journal-title":"J. Biol. Chem."},{"issue":"4","key":"29070_CR34","doi-asserted-by":"publisher","first-page":"111505","DOI":"10.1016\/j.celrep.2022.111505","volume":"41","author":"CM Rodriguez","year":"2022","unstructured":"Rodriguez, C. M. et al. Targeting RTN4\/NoGo-Receptor reduces levels of ALS protein ataxin-2. Cell. Rep. 41 (4), 111505 (2022).","journal-title":"Cell. Rep."},{"issue":"4","key":"29070_CR35","doi-asserted-by":"publisher","first-page":"111508","DOI":"10.1016\/j.celrep.2022.111508","volume":"41","author":"G Kim","year":"2022","unstructured":"Kim, G. et al. Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2. Cell. Rep. 41 (4), 111508 (2022).","journal-title":"Cell. Rep."},{"issue":"7650","key":"29070_CR36","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature22044","volume":"544","author":"DR Scoles","year":"2017","unstructured":"Scoles, D. R. et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature 544 (7650), 362\u2013366 (2017).","journal-title":"Nature"},{"issue":"7650","key":"29070_CR37","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nature22038","volume":"544","author":"LA Becker","year":"2017","unstructured":"Becker, L. A. et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544 (7650), 367\u2013371 (2017).","journal-title":"Nature"},{"issue":"1","key":"29070_CR38","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1038\/s41467-023-42147-z","volume":"14","author":"CM Zeballos","year":"2023","unstructured":"Zeballos, C. M. et al. Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins. Nat. Commun. 14 (1), 6492 (2023).","journal-title":"Nat. Commun."},{"issue":"2","key":"29070_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12311-019-01092-8","volume":"19","author":"JH Wardman","year":"2020","unstructured":"Wardman, J. H. et al. Enhancement of autophagy and solubilization of Ataxin-2 alleviate apoptosis in spinocerebellar ataxia type 2 patient cells. Cerebellum 19 (2), 165\u2013181 (2020).","journal-title":"Cerebellum"},{"key":"29070_CR40","doi-asserted-by":"publisher","first-page":"12166","DOI":"10.1038\/srep12166","volume":"5","author":"AL Southwell","year":"2015","unstructured":"Southwell, A. L. et al. Ultrasensitive measurement of Huntingtin protein in cerebrospinal fluid demonstrates increase with huntington disease stage and decrease following brain Huntingtin suppression. Sci. Rep. 5, 12166 (2015).","journal-title":"Sci. Rep."},{"issue":"4","key":"29070_CR41","doi-asserted-by":"publisher","first-page":"e0266812","DOI":"10.1371\/journal.pone.0266812","volume":"17","author":"DF Fischer","year":"2022","unstructured":"Fischer, D. F. et al. Development of mAb-based polyglutamine-dependent and polyglutamine length-independent Huntingtin quantification assays with cross-site validation. PLoS One. 17 (4), e0266812 (2022).","journal-title":"PLoS One"},{"issue":"11","key":"29070_CR42","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/mds.28749","volume":"36","author":"J H\u00fcbener-Schmid","year":"2021","unstructured":"H\u00fcbener-Schmid, J. et al. Polyglutamine-Expanded Ataxin-3: A target engagement marker for spinocerebellar ataxia type 3 in peripheral blood. Mov. Disord. 36 (11), 2675\u20132681 (2021).","journal-title":"Mov. Disord"},{"key":"29070_CR43","unstructured":"The Genotype-Tissue expression (GTEx) project. Nat. Genet., 45(6): pp. 580\u2013585. (2013)."},{"issue":"6","key":"29070_CR44","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s12035-023-03294-y","volume":"60","author":"J Bux","year":"2023","unstructured":"Bux, J. et al. TR-FRET-Based immunoassay to measure Ataxin-2 as a target engagement marker in spinocerebellar ataxia type 2. Mol. Neurobiol. 60 (6), 3553\u20133567 (2023).","journal-title":"Mol. Neurobiol."},{"key":"29070_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.nbd.2016.09.002","volume":"96","author":"NE Sen","year":"2016","unstructured":"Sen, N. E. et al. Search for SCA2 blood RNA biomarkers highlights Ataxin-2 as strong modifier of the mitochondrial factor PINK1 levels. Neurobiol. Dis. 96, 115\u2013126 (2016).","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"29070_CR46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10072-017-3156-6","volume":"39","author":"G Puorro","year":"2018","unstructured":"Puorro, G. et al. Peripheral markers of autophagy in polyglutamine diseases. Neurol. Sci. 39 (1), 149\u2013152 (2018).","journal-title":"Neurol. Sci."},{"key":"29070_CR47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jtemb.2018.02.011","volume":"47","author":"S Squadrone","year":"2018","unstructured":"Squadrone, S. et al. Altered homeostasis of trace elements in the blood of SCA2 patients. J. Trace Elem. Med. Biol. 47, 111\u2013114 (2018).","journal-title":"J. Trace Elem. Med. Biol."},{"key":"29070_CR48","doi-asserted-by":"publisher","first-page":"p9875639","DOI":"10.1155\/2021\/9875639","volume":"2021","author":"AG Dennis","year":"2021","unstructured":"Dennis, A. G. et al. Redox imbalance associates with clinical worsening in spinocerebellar ataxia type 2. Oxid. Med. Cell. Longev. 2021, p9875639 (2021).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"29070_CR49","doi-asserted-by":"publisher","first-page":"106112","DOI":"10.1016\/j.nbd.2023.106112","volume":"181","author":"XN Shen","year":"2023","unstructured":"Shen, X. N. et al. Systematic assessment of plasma biomarkers in spinocerebellar ataxia. Neurobiol. Dis. 181, 106112 (2023).","journal-title":"Neurobiol. Dis."},{"issue":"24","key":"29070_CR50","doi-asserted-by":"publisher","first-page":"e2404","DOI":"10.1212\/WNL.0000000000012945","volume":"97","author":"L Yang","year":"2021","unstructured":"Yang, L. et al. Association of the level of neurofilament light with disease severity in patients with spinocerebellar ataxia type 2. Neurology 97 (24), e2404\u2013e2413 (2021).","journal-title":"Neurology"},{"key":"29070_CR51","doi-asserted-by":"publisher","first-page":"105311","DOI":"10.1016\/j.nbd.2021.105311","volume":"153","author":"G Coarelli","year":"2021","unstructured":"Coarelli, G. et al. Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia. Neurobiol. Dis. 153, 105311 (2021).","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"29070_CR52","doi-asserted-by":"publisher","first-page":"e209749","DOI":"10.1212\/WNL.0000000000209749","volume":"103","author":"G Coarelli","year":"2024","unstructured":"Coarelli, G. et al. Longitudinal changes of Clinical, Imaging, and fluid biomarkers in preataxic and early ataxic spinocerebellar ataxia type 2 and 7 carriers. Neurology 103 (5), e209749 (2024).","journal-title":"Neurology"},{"issue":"1","key":"29070_CR53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/mds.28783","volume":"37","author":"L Peng","year":"2022","unstructured":"Peng, L. et al. Blood neurofilament light chain in genetic ataxia: A Meta-Analysis. Mov. Disord. 37 (1), 171\u2013181 (2022).","journal-title":"Mov. Disord"},{"key":"29070_CR54","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3389\/fneur.2020.00919","volume":"11","author":"Q Sun","year":"2020","unstructured":"Sun, Q. et al. CSF neurofilament light chain elevation predicts ALS severity and progression. Front. Neurol. 11, 919 (2020).","journal-title":"Front. Neurol."},{"key":"29070_CR55","doi-asserted-by":"publisher","first-page":"1132808","DOI":"10.3389\/fnagi.2023.1132808","volume":"15","author":"F Verde","year":"2023","unstructured":"Verde, F. et al. Phenotypic correlates of serum neurofilament light chain levels in amyotrophic lateral sclerosis. Front. Aging Neurosci. 15, 1132808 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"29070_CR56","doi-asserted-by":"publisher","first-page":"1420198","DOI":"10.3389\/fnins.2024.1420198","volume":"18","author":"M Machacek","year":"2024","unstructured":"Machacek, M. et al. NfL concentration in CSF is a quantitative marker of the rate of neurodegeneration in aging and huntington\u2019s disease: a semi-mechanistic model-based analysis. Front. Neurosci. 18, 1420198 (2024).","journal-title":"Front. Neurosci."},{"issue":"17","key":"29070_CR57","doi-asserted-by":"publisher","first-page":"e1836","DOI":"10.1212\/WNL.0000000000207088","volume":"100","author":"S Tezenas du Montcel","year":"2023","unstructured":"Tezenas du Montcel, S. et al. Baseline clinical and blood biomarkers in patients with preataxic and Early-Stage disease spinocerebellar ataxia 1 and 3. Neurology 100 (17), e1836\u2013e1848 (2023).","journal-title":"Neurology"},{"issue":"12","key":"29070_CR58","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller, T. M. et al. Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl. J. Med. 387 (12), 1099\u20131110 (2022).","journal-title":"N Engl. J. Med."},{"issue":"6","key":"29070_CR59","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/mus.27818","volume":"67","author":"T Meyer","year":"2023","unstructured":"Meyer, T. et al. Neurofilament light-chain response during therapy with antisense oligonucleotide Tofersen in SOD1-related ALS: Treatment experience in clinical practice. Muscle Nerve. 67 (6), 515\u2013521 (2023).","journal-title":"Muscle Nerve"},{"issue":"23","key":"29070_CR60","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMc2300400","volume":"389","author":"P McColgan","year":"2023","unstructured":"McColgan, P. et al. Tominersen in adults with manifest Huntington\u2019s disease. N Engl. J. Med. 389 (23), 2203\u20132205 (2023).","journal-title":"N Engl. J. Med."},{"issue":"24","key":"29070_CR61","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J. et al. Targeting Huntingtin expression in patients with Huntington\u2019s disease. N Engl. J. Med. 380 (24), 2307\u20132316 (2019).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"29070_CR62","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12311-025-01856-5","volume":"24","author":"T Klockgether","year":"2025","unstructured":"Klockgether, T., Grobe-Einsler, M. & Faber, J. Biomarkers in spinocerebellar ataxias. Cerebellum 24 (4), 104 (2025).","journal-title":"Cerebellum"},{"issue":"1","key":"29070_CR63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12311-021-01257-4","volume":"21","author":"H Donath","year":"2022","unstructured":"Donath, H. et al. Neurofilament light chain is a biomarker of neurodegeneration in ataxia telangiectasia. Cerebellum 21 (1), 39\u201347 (2022).","journal-title":"Cerebellum"},{"key":"29070_CR64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/bs.acc.2025.01.006","volume":"126","author":"AJ Uzgiris","year":"2025","unstructured":"Uzgiris, A. J., Ladic, L. A. & Pfister, S. X. Advances in neurofilament light chain analysis. Adv. Clin. Chem. 126, 31\u201371 (2025).","journal-title":"Adv. Clin. Chem."},{"issue":"4","key":"29070_CR65","doi-asserted-by":"publisher","first-page":"e200427","DOI":"10.1212\/NXI.0000000000200427","volume":"12","author":"A Bar-Or","year":"2025","unstructured":"Bar-Or, A. et al. Exploring the clinical utility of neurofilament light chain assays in multiple sclerosis management. Neurol. Neuroimmunol. Neuroinflamm. 12 (4), e200427 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"29070_CR66","doi-asserted-by":"publisher","first-page":"654942","DOI":"10.3389\/fnins.2021.654942","volume":"15","author":"S Thebault","year":"2021","unstructured":"Thebault, S. et al. Serum neurofilament light chain measurement in MS: hurdles to clinical translation. Front. Neurosci. 15, 654942 (2021).","journal-title":"Front. Neurosci."},{"issue":"2","key":"29070_CR67","doi-asserted-by":"publisher","first-page":"e000063","DOI":"10.1136\/bmjno-2020-000063","volume":"2","author":"T Sejbaek","year":"2020","unstructured":"Sejbaek, T. et al. Comparison of neurofilament light chain results between two independent facilities. BMJ Neurol. Open. 2 (2), e000063 (2020).","journal-title":"BMJ Neurol. Open."},{"issue":"6","key":"29070_CR68","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28 (6), 595\u2013599 (2010).","journal-title":"Nat. Biotechnol."},{"key":"29070_CR69","doi-asserted-by":"publisher","first-page":"1414886","DOI":"10.3389\/fnmol.2024.1414886","volume":"17","author":"C Carraro","year":"2024","unstructured":"Carraro, C. et al. Tackling neurodegeneration in vitro with omics: a path towards new targets and drugs. Front. Mol. Neurosci. 17, 1414886 (2024).","journal-title":"Front. Mol. Neurosci."},{"key":"29070_CR70","doi-asserted-by":"publisher","first-page":"686722","DOI":"10.3389\/fncel.2021.686722","volume":"15","author":"A Di Paolo","year":"2021","unstructured":"Di Paolo, A. et al. Functional genomics of axons and synapses to understand neurodegenerative diseases. Front. Cell. Neurosci. 15, 686722 (2021).","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"29070_CR71","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13195-024-01578-6","volume":"16","author":"L Meng","year":"2024","unstructured":"Meng, L. et al. Multi-omics analysis reveals the key factors involved in the severity of the alzheimer\u2019s disease. Alzheimers Res. Ther. 16 (1), 213 (2024).","journal-title":"Alzheimers Res. Ther."},{"key":"29070_CR72","doi-asserted-by":"publisher","first-page":"106698","DOI":"10.1016\/j.nbd.2024.106698","volume":"202","author":"F Carrillo","year":"2024","unstructured":"Carrillo, F. et al. Multiomics approach discloses lipids and metabolites profiles associated to parkinson\u2019s disease stages and applied therapies. Neurobiol. Dis. 202, 106698 (2024).","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"29070_CR73","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1089\/omi.2017.0183","volume":"22","author":"K Mitropoulos","year":"2018","unstructured":"Mitropoulos, K. et al. Multi-Omics for biomarker discovery and target validation in biofluids for amyotrophic lateral sclerosis diagnosis. Omics 22 (1), 52\u201364 (2018).","journal-title":"Omics"},{"issue":"1","key":"29070_CR74","doi-asserted-by":"publisher","first-page":"6742","DOI":"10.1038\/s41467-024-50626-0","volume":"15","author":"F Paryani","year":"2024","unstructured":"Paryani, F. et al. Multi-omic analysis of huntington\u2019s disease reveals a compensatory astrocyte state. Nat. Commun. 15 (1), 6742 (2024).","journal-title":"Nat. Commun."},{"key":"29070_CR75","doi-asserted-by":"crossref","unstructured":"Arsovi\u0107, A. et al. Mouse Ataxin-2 expansion downregulates camkii and other calcium signaling Factors, impairing Granule-Purkinje neuron synaptic strength. Int. J. Mol. Sci., 21(18). (2020).","DOI":"10.3390\/ijms21186673"},{"key":"29070_CR76","doi-asserted-by":"publisher","first-page":"105289","DOI":"10.1016\/j.nbd.2021.105289","volume":"152","author":"J Canet-Pons","year":"2021","unstructured":"Canet-Pons, J. et al. Atxn2-CAG100-KnockIn mouse spinal cord shows progressive TDP43 pathology associated with cholesterol biosynthesis suppression. Neurobiol. Dis. 152, 105289 (2021).","journal-title":"Neurobiol. Dis."},{"issue":"8","key":"29070_CR77","doi-asserted-by":"publisher","first-page":"e1002920","DOI":"10.1371\/journal.pgen.1002920","volume":"8","author":"E Damrath","year":"2012","unstructured":"Damrath, E. et al. ATXN2-CAG42 sequesters PABPC1 into insolubility and induces FBXW8 in cerebellum of old ataxic knock-in mice. PLoS Genet. 8 (8), e1002920 (2012).","journal-title":"PLoS Genet."},{"issue":"3","key":"29070_CR78","doi-asserted-by":"publisher","first-page":"e0121089","DOI":"10.1371\/journal.pone.0121089","volume":"10","author":"MV Halbach","year":"2015","unstructured":"Halbach, M. V. et al. Both ubiquitin ligases FBXW8 and PARK2 are sequestrated into insolubility by ATXN2 PolyQ expansions, but only FBXW8 expression is dysregulated. PLoS One. 10 (3), e0121089 (2015).","journal-title":"PLoS One"},{"issue":"1","key":"29070_CR79","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12311-016-0762-4","volume":"16","author":"MV Halbach","year":"2017","unstructured":"Halbach, M. V. et al. Atxn2 knockout and CAG42-Knock-in cerebellum shows similarly dysregulated expression in calcium homeostasis pathway. Cerebellum 16 (1), 68\u201381 (2017).","journal-title":"Cerebellum"},{"key":"29070_CR80","doi-asserted-by":"publisher","first-page":"106903","DOI":"10.1016\/j.nbd.2025.106903","volume":"209","author":"J Key","year":"2025","unstructured":"Key, J. et al. ATXN2L primarily interacts with NUFIP2, the absence of ATXN2L results in NUFIP2 depletion, and the ATXN2-polyQ expansion triggers NUFIP2 accumulation. Neurobiol. Dis. 209, 106903 (2025).","journal-title":"Neurobiol. Dis."},{"key":"29070_CR81","first-page":"95","volume-title":"Handbook of Animal Models in Neurological Disorders","author":"NE Sen","year":"2022","unstructured":"Sen, N. E. & Auburger, G. Modeling amyotrophic lateral sclerosis through Ataxin-2 pathology, in Handbook of Animal Models in Neurological Disorders, C.R. Martin, V.B. Patel, and V.R. Preedy, Editors. Elsevier Academic: Cambridge, MA. 95\u2013106. (2022)."},{"issue":"Pt 4","key":"29070_CR82","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/brain\/121.4.589","volume":"121","author":"T Klockgether","year":"1998","unstructured":"Klockgether, T. et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 121 (Pt 4), 589\u2013600 (1998).","journal-title":"Brain"},{"issue":"11","key":"29070_CR83","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S1474-4422(15)00202-1","volume":"14","author":"H Jacobi","year":"2015","unstructured":"Jacobi, H. et al. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol. 14 (11), 1101\u20131108 (2015).","journal-title":"Lancet Neurol."},{"issue":"3","key":"29070_CR84","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10048-015-0441-5","volume":"16","author":"M Fittschen","year":"2015","unstructured":"Fittschen, M. et al. Genetic ablation of ataxin-2 increases several global translation factors in their transcript abundance but decreases translation rate. Neurogenetics 16 (3), 181\u2013192 (2015).","journal-title":"Neurogenetics"},{"issue":"15","key":"29070_CR85","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1016\/j.cell.2023.05.045","volume":"186","author":"Y Zhuang","year":"2023","unstructured":"Zhuang, Y. et al. Circadian clocks are modulated by compartmentalized oscillating translation. Cell 186 (15), 3245\u20133260e23 (2023).","journal-title":"Cell"},{"issue":"4","key":"29070_CR86","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1091\/mbc.e06-12-1120","volume":"18","author":"U Nonhoff","year":"2007","unstructured":"Nonhoff, U. et al. Ataxin-2 interacts with the DEAD\/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol. Biol. Cell. 18 (4), 1385\u20131396 (2007).","journal-title":"Mol. Biol. Cell."},{"issue":"4","key":"29070_CR87","doi-asserted-by":"publisher","first-page":"e10006","DOI":"10.1371\/journal.pone.0010006","volume":"5","author":"KD Swisher","year":"2010","unstructured":"Swisher, K. D. & Parker, R. Localization to, and effects of Pbp1, Pbp4, Lsm12, Dhh1, and Pab1 on stress granules in Saccharomyces cerevisiae. PLoS One. 5 (4), e10006 (2010).","journal-title":"PLoS One"},{"issue":"2","key":"29070_CR88","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.molcel.2014.05.022","volume":"55","author":"M Yokoshi","year":"2014","unstructured":"Yokoshi, M. et al. Direct binding of Ataxin-2 to distinct elements in 3\u2019 UTRs promotes mRNA stability and protein expression. Mol. Cell. 55 (2), 186\u2013198 (2014).","journal-title":"Mol. Cell."},{"key":"29070_CR89","doi-asserted-by":"crossref","unstructured":"Baldarelli, R. M. et al. Mouse genome informatics: an integrated knowledgebase system for the laboratory mouse. Genetics, 227(1). (2024).","DOI":"10.1093\/genetics\/iyae031"},{"issue":"14","key":"29070_CR90","doi-asserted-by":"publisher","first-page":"9036","DOI":"10.1021\/acs.chemrev.2c00608","volume":"123","author":"SR Millar","year":"2023","unstructured":"Millar, S. R. et al. A new phase of networking: the molecular composition and regulatory dynamics of mammalian stress granules. Chem. Rev. 123 (14), 9036\u20139064 (2023).","journal-title":"Chem. Rev."},{"issue":"1","key":"29070_CR91","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12031-012-9949-4","volume":"51","author":"J Drost","year":"2013","unstructured":"Drost, J. et al. Ataxin-2 modulates the levels of Grb2 and SRC but not Ras signaling. J. Mol. Neurosci. 51 (1), 68\u201381 (2013).","journal-title":"J. Mol. Neurosci."},{"issue":"4","key":"29070_CR92","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10048-018-0557-5","volume":"19","author":"J Canet-Pons","year":"2018","unstructured":"Canet-Pons, J. et al. Ataxia telangiectasia alters the ApoB and reelin pathway. Neurogenetics 19 (4), 237\u2013255 (2018).","journal-title":"Neurogenetics"},{"issue":"10","key":"29070_CR93","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/hmg\/ddaa072","volume":"29","author":"DR Scoles","year":"2020","unstructured":"Scoles, D. R. et al. ALS-associated genes in SCA2 mouse spinal cord transcriptomes. Hum. Mol. Genet. 29 (10), 1658\u20131672 (2020).","journal-title":"Hum. Mol. Genet."},{"issue":"16","key":"29070_CR94","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1093\/hmg\/ddx191","volume":"26","author":"LT Pflieger","year":"2017","unstructured":"Pflieger, L. T. et al. Gene co-expression network analysis for identifying modules and functionally enriched pathways in SCA2. Hum. Mol. Genet. 26 (16), 3069\u20133080 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"29070_CR95","doi-asserted-by":"crossref","unstructured":"Key, J. et al. Conditional ATXN2L-Null in Adult Frontal Cortex CamK2a\u2009+\u2009Neurons Does Not Cause Cell Death but Restricts Spontaneous Mobility and Affects the Alternative Splicing Pathway. Cells, 14(19). (2025).","DOI":"10.3390\/cells14191532"},{"issue":"Pt 3","key":"29070_CR96","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/brain\/awf060","volume":"125","author":"JT Pang","year":"2002","unstructured":"Pang, J. T. et al. Neuronal intranuclear inclusions in SCA2: a genetic, morphological and immunohistochemical study of two cases. Brain 125 (Pt 3), 656\u2013663 (2002).","journal-title":"Brain"},{"issue":"5","key":"29070_CR97","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1440-1789.2010.01176.x","volume":"31","author":"C Ishida","year":"2011","unstructured":"Ishida, C. et al. An autopsy case of an aged patient with spinocerebellar ataxia type 2. Neuropathology 31 (5), 510\u2013518 (2011).","journal-title":"Neuropathology"},{"issue":"4","key":"29070_CR98","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-014-1277-z","volume":"128","author":"D B\u00e4umer","year":"2014","unstructured":"B\u00e4umer, D. et al. FTLD-ALS of TDP-43 type and SCA2 in a family with a full ataxin-2 polyglutamine expansion. Acta Neuropathol. 128 (4), 597\u2013604 (2014).","journal-title":"Acta Neuropathol."},{"issue":"12","key":"29070_CR99","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.clinph.2017.10.009","volume":"128","author":"L Vel\u00e1zquez-P\u00e9rez","year":"2017","unstructured":"Vel\u00e1zquez-P\u00e9rez, L. et al. Early corticospinal tract damage in prodromal SCA2 revealed by EEG-EMG and EMG-EMG coherence. Clin. Neurophysiol. 128 (12), 2493\u20132502 (2017).","journal-title":"Clin. Neurophysiol."},{"issue":"3","key":"29070_CR100","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/mus.26613","volume":"60","author":"L Pelosi","year":"2019","unstructured":"Pelosi, L. et al. Spinocerebellar ataxia type 2-neuronopathy or neuropathy? Muscle Nerve. 60 (3), 271\u2013278 (2019).","journal-title":"Muscle Nerve"},{"issue":"7","key":"29070_CR101","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1136\/jnnp-2023-332696","volume":"95","author":"TJR Rezende","year":"2024","unstructured":"Rezende, T. J. R. et al. Genotype-specific spinal cord damage in spinocerebellar ataxias: an ENIGMA-Ataxia study. J. Neurol. Neurosurg. Psychiatry. 95 (7), 682\u2013690 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"29070_CR102","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00018-003-3240-3","volume":"61","author":"GA Silverman","year":"2004","unstructured":"Silverman, G. A. et al. Human clade B Serpins (ov-serpins) belong to a cohort of evolutionarily dispersed intracellular proteinase inhibitor clades that protect cells from promiscuous proteolysis. Cell. Mol. Life Sci. 61 (3), 301\u2013325 (2004).","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"29070_CR103","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41590-018-0303-z","volume":"20","author":"YJ Choi","year":"2019","unstructured":"Choi, Y. J. et al. SERPINB1-mediated checkpoint of inflammatory caspase activation. Nat. Immunol. 20 (3), 276\u2013287 (2019).","journal-title":"Nat. Immunol."},{"issue":"12","key":"29070_CR104","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1016\/j.celrep.2019.05.065","volume":"27","author":"SS Burgener","year":"2019","unstructured":"Burgener, S. S. et al. Cathepsin G Inhibition by Serpinb1 and Serpinb6 prevents programmed necrosis in neutrophils and monocytes and reduces GSDMD-Driven inflammation. Cell. Rep. 27 (12), 3646\u20133656e5 (2019).","journal-title":"Cell. Rep."},{"issue":"19","key":"29070_CR105","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1182\/blood-2012-09-455022","volume":"121","author":"M Baumann","year":"2013","unstructured":"Baumann, M., Pham, C. T. & Benarafa, C. SerpinB1 is critical for neutrophil survival through cell-autonomous Inhibition of cathepsin G. Blood 121 (19), 3900\u20133907 (2013).","journal-title":"Blood"},{"issue":"10","key":"29070_CR106","doi-asserted-by":"publisher","first-page":"e0104523","DOI":"10.1128\/jvi.01045-23","volume":"97","author":"J Yan","year":"2023","unstructured":"Yan, J. et al. SERPINB1 promotes senecavirus A replication by degrading IKBKE and regulating the IFN pathway via autophagy. J. Virol. 97 (10), e0104523 (2023).","journal-title":"J. Virol."},{"issue":"6","key":"29070_CR107","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1007\/s12035-022-02817-3","volume":"59","author":"M Zattoni","year":"2022","unstructured":"Zattoni, M. et al. Serpin signatures in prion and alzheimer\u2019s diseases. Mol. Neurobiol. 59 (6), 3778\u20133799 (2022).","journal-title":"Mol. Neurobiol."},{"issue":"6","key":"29070_CR108","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00401-018-1881-4","volume":"136","author":"Y Deming","year":"2018","unstructured":"Deming, Y. et al. Sex-specific genetic predictors of alzheimer\u2019s disease biomarkers. Acta Neuropathol. 136 (6), 857\u2013872 (2018).","journal-title":"Acta Neuropathol."},{"issue":"11","key":"29070_CR109","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/jnnp-2023-331142","volume":"94","author":"WM Su","year":"2023","unstructured":"Su, W. M. et al. Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for alzheimer\u2019s disease. J. Neurol. Neurosurg. Psychiatry. 94 (11), 954\u2013961 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"29070_CR110","doi-asserted-by":"publisher","first-page":"116618","DOI":"10.1016\/j.biopha.2024.116618","volume":"175","author":"S Janciauskiene","year":"2024","unstructured":"Janciauskiene, S. et al. Diagnostic and therapeutic value of human Serpin family proteins. Biomed. Pharmacother. 175, 116618 (2024).","journal-title":"Biomed. Pharmacother"},{"issue":"2","key":"29070_CR111","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/med.21451","volume":"38","author":"N Masurier","year":"2018","unstructured":"Masurier, N. et al. Inhibitors of kallikrein-related peptidases: an overview. Med. Res. Rev. 38 (2), 655\u2013683 (2018).","journal-title":"Med. Res. Rev."},{"issue":"6806","key":"29070_CR112","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/35038119","volume":"407","author":"JA Huntington","year":"2000","unstructured":"Huntington, J. A., Read, R. J. & Carrell, R. W. Structure of a serpin-protease complex shows Inhibition by deformation. Nature 407 (6806), 923\u2013926 (2000).","journal-title":"Nature"},{"issue":"1","key":"29070_CR113","first-page":"C106","volume":"320","author":"A S\u00e1nchez-Navarro","year":"2021","unstructured":"S\u00e1nchez-Navarro, A. et al. An integrative view of Serpins in health and disease: the contribution of SerpinA3. Am. J. Physiol. Cell. Physiol. 320 (1), C106\u2013c118 (2021).","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"29070_CR114","doi-asserted-by":"crossref","unstructured":"Olejniczak, M., Urbanek, M. O. & Krzyzosiak, W. J. The role of the immune system in triplet repeat expansion diseases. Mediators Inflamm, 2015: p. 873860. (2015).","DOI":"10.1155\/2015\/873860"},{"issue":"3","key":"29070_CR115","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.neuron.2023.01.007","volume":"111","author":"A Yadav","year":"2023","unstructured":"Yadav, A. et al. A cellular taxonomy of the adult human spinal cord. Neuron 111 (3), 328\u2013344 (2023). .e7.","journal-title":"Neuron"},{"issue":"1","key":"29070_CR116","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.1038\/s41467-021-25125-1","volume":"12","author":"DE Russ","year":"2021","unstructured":"Russ, D. E. et al. A harmonized atlas of mouse spinal cord cell types and their Spatial organization. Nat. Commun. 12 (1), 5722 (2021).","journal-title":"Nat. Commun."},{"issue":"1","key":"29070_CR117","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1038\/s41467-024-48961-3","volume":"15","author":"J H\u00e4llqvist","year":"2024","unstructured":"H\u00e4llqvist, J. et al. Plasma proteomics identify biomarkers predicting parkinson\u2019s disease up to 7 years before symptom onset. Nat. Commun. 15 (1), 4759 (2024).","journal-title":"Nat. Commun."},{"key":"29070_CR118","doi-asserted-by":"crossref","unstructured":"Onur, T. S. et al. Downregulation of glial genes involved in synaptic function mitigates Huntington\u2019s disease pathogenesis. Elife, 10. (2021).","DOI":"10.7554\/eLife.64564"},{"issue":"1","key":"29070_CR119","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41593-022-01205-3","volume":"26","author":"J Humphrey","year":"2023","unstructured":"Humphrey, J. et al. Integrative transcriptomic analysis of the amyotrophic lateral sclerosis spinal cord implicates glial activation and suggests new risk genes. Nat. Neurosci. 26 (1), 150\u2013162 (2023).","journal-title":"Nat. Neurosci."},{"issue":"11","key":"29070_CR120","doi-asserted-by":"publisher","first-page":"e0167428","DOI":"10.1371\/journal.pone.0167428","volume":"11","author":"S Cermak","year":"2016","unstructured":"Cermak, S. et al. Loss of cathepsin B and L leads to lysosomal Dysfunction, NPC-Like cholesterol sequestration and accumulation of the key alzheimer\u2019s proteins. PLoS One. 11 (11), e0167428 (2016).","journal-title":"PLoS One"},{"issue":"7","key":"29070_CR121","doi-asserted-by":"publisher","first-page":"119243","DOI":"10.1016\/j.bbamcr.2022.119243","volume":"1869","author":"A Drobny","year":"2022","unstructured":"Drobny, A. et al. The role of lysosomal cathepsins in neurodegeneration: mechanistic insights, diagnostic potential and therapeutic approaches. Biochim. Biophys. Acta Mol. Cell. Res. 1869 (7), 119243 (2022).","journal-title":"Biochim. Biophys. Acta Mol. Cell. Res."},{"issue":"5","key":"29070_CR122","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/15548627.2022.2045534","volume":"18","author":"S Prieto Huarcaya","year":"2022","unstructured":"Prieto Huarcaya, S. et al. Recombinant pro-CTSD (cathepsin D) enhances SNCA\/\u03b1-Synuclein degradation in \u03b1-Synucleinopathy models. Autophagy 18 (5), 1127\u20131151 (2022).","journal-title":"Autophagy"},{"issue":"1","key":"29070_CR123","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41467-022-35494-w","volume":"14","author":"J Eshima","year":"2023","unstructured":"Eshima, J. et al. Molecular subtypes of ALS are associated with differences in patient prognosis. Nat. Commun. 14 (1), 95 (2023).","journal-title":"Nat. Commun."},{"issue":"19\u201320","key":"29070_CR124","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1007\/s00018-021-03907-6","volume":"78","author":"E D\u2019Acunto","year":"2021","unstructured":"D\u2019Acunto, E. et al. Neuroserpin: structure, function, physiology and pathology. Cell. Mol. Life Sci. 78 (19\u201320), 6409\u20136430 (2021).","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"29070_CR125","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1046\/j.1471-4159.2002.01100.x","volume":"82","author":"PK Parmar","year":"2002","unstructured":"Parmar, P. K. et al. Neuroserpin regulates neurite outgrowth in nerve growth factor-treated PC12 cells. J. Neurochem. 82 (6), 1406\u20131415 (2002).","journal-title":"J. Neurochem"},{"issue":"4","key":"29070_CR126","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1074\/jbc.273.4.2312","volume":"273","author":"T Osterwalder","year":"1998","unstructured":"Osterwalder, T. et al. The axonally secreted Serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin. J. Biol. Chem. 273 (4), 2312\u20132321 (1998).","journal-title":"J. Biol. Chem."},{"issue":"3","key":"29070_CR127","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00018-022-04185-6","volume":"79","author":"A Godinez","year":"2022","unstructured":"Godinez, A. et al. Neuroserpin, a crucial regulator for axogenesis, synaptic modelling and cell-cell interactions in the pathophysiology of neurological disease. Cell. Mol. Life Sci. 79 (3), 172 (2022).","journal-title":"Cell. Mol. Life Sci."},{"key":"29070_CR128","doi-asserted-by":"publisher","first-page":"103420","DOI":"10.1016\/j.mcn.2019.103420","volume":"102","author":"M Hermann","year":"2020","unstructured":"Hermann, M. et al. Deficits in developmental neurogenesis and dendritic spine maturation in mice lacking the Serine protease inhibitor neuroserpin. Mol. Cell. Neurosci. 102, 103420 (2020).","journal-title":"Mol. Cell. Neurosci."},{"issue":"9","key":"29070_CR129","doi-asserted-by":"publisher","first-page":"140465","DOI":"10.1016\/j.bbapap.2020.140465","volume":"1868","author":"H Nakanishi","year":"2020","unstructured":"Nakanishi, H. Cathepsin regulation on microglial function. Biochim. Biophys. Acta Proteins Proteom. 1868 (9), 140465 (2020).","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"29070_CR130","doi-asserted-by":"crossref","unstructured":"Yadati, T. et al. The Ins and outs of cathepsins: physiological function and role in disease management. Cells, 9(7). (2020).","DOI":"10.3390\/cells9071679"},{"issue":"19","key":"29070_CR131","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.1523\/JNEUROSCI.20-19-07268.2000","volume":"20","author":"KB Kegel","year":"2000","unstructured":"Kegel, K. B. et al. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J. Neurosci. 20 (19), 7268\u20137278 (2000).","journal-title":"J. Neurosci."},{"key":"29070_CR132","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1750-1326-5-58","volume":"5","author":"KB Kegel","year":"2010","unstructured":"Kegel, K. B. et al. Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors. Mol. Neurodegener. 5, 58 (2010).","journal-title":"Mol. Neurodegener"},{"issue":"2","key":"29070_CR133","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.nbd.2005.11.012","volume":"22","author":"YJ Kim","year":"2006","unstructured":"Kim, Y. J. et al. Lysosomal proteases are involved in generation of N-terminal Huntingtin fragments. Neurobiol. Dis. 22 (2), 346\u2013356 (2006).","journal-title":"Neurobiol. Dis."},{"key":"29070_CR134","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1750-1326-6-37","volume":"6","author":"Q Liang","year":"2011","unstructured":"Liang, Q. et al. Reduction of mutant Huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons. Mol. Neurodegener. 6, 37 (2011).","journal-title":"Mol. Neurodegener"},{"issue":"24","key":"29070_CR135","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1093\/hmg\/ddg346","volume":"12","author":"ZH Qin","year":"2003","unstructured":"Qin, Z. H. et al. Autophagy regulates the processing of amino terminal Huntingtin fragments. Hum. Mol. Genet. 12 (24), 3231\u20133244 (2003).","journal-title":"Hum. Mol. Genet."},{"issue":"21","key":"29070_CR136","doi-asserted-by":"publisher","first-page":"17471","DOI":"10.1074\/jbc.M112.352781","volume":"287","author":"N Bhutani","year":"2012","unstructured":"Bhutani, N. et al. Cathepsins L and Z are critical in degrading polyglutamine-containing proteins within lysosomes. J. Biol. Chem. 287 (21), 17471\u201317482 (2012).","journal-title":"J. Biol. Chem."},{"issue":"12","key":"29070_CR137","doi-asserted-by":"publisher","first-page":"e0296085","DOI":"10.1371\/journal.pone.0296085","volume":"18","author":"M Chitre","year":"2023","unstructured":"Chitre, M. & Emery, P. ATXN2 is a target of N-terminal proteolysis. PLoS One. 18 (12), e0296085 (2023).","journal-title":"PLoS One"},{"issue":"6","key":"29070_CR138","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/brain\/awad280","volume":"147","author":"ST Brady","year":"2024","unstructured":"Brady, S. T. et al. Toxic effects of mutant Huntingtin in axons are mediated by its proline-rich domain. Brain 147 (6), 2098\u20132113 (2024).","journal-title":"Brain"},{"issue":"36","key":"29070_CR139","doi-asserted-by":"publisher","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","volume":"28","author":"AL Southwell","year":"2008","unstructured":"Southwell, A. L. et al. Intrabodies binding the proline-rich domains of mutant Huntingtin increase its turnover and reduce neurotoxicity. J. Neurosci. 28 (36), 9013\u20139020 (2008).","journal-title":"J. Neurosci."},{"issue":"47","key":"29070_CR140","doi-asserted-by":"publisher","first-page":"35608","DOI":"10.1074\/jbc.M605558200","volume":"281","author":"B Dehay","year":"2006","unstructured":"Dehay, B. & Bertolotti, A. Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast. J. Biol. Chem. 281 (47), 35608\u201335615 (2006).","journal-title":"J. Biol. Chem."},{"issue":"5","key":"29070_CR141","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/biot.200600249","volume":"2","author":"B Dehay","year":"2007","unstructured":"Dehay, B. et al. Mapping of the epitope of monoclonal antibody 2B4 to the proline-rich region of human Huntingtin, a region critical for aggregation and toxicity. Biotechnol. J. 2 (5), 559\u2013564 (2007).","journal-title":"Biotechnol. J."},{"issue":"27","key":"29070_CR142","doi-asserted-by":"publisher","first-page":"24562","DOI":"10.1074\/jbc.M202392200","volume":"277","author":"MJ Bernett","year":"2002","unstructured":"Bernett, M. J. et al. Crystal structure and biochemical characterization of human Kallikrein 6 reveals that a trypsin-like Kallikrein is expressed in the central nervous system. J. Biol. Chem. 277 (27), 24562\u201324570 (2002).","journal-title":"J. Biol. Chem."},{"issue":"4","key":"29070_CR143","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1021\/bi015781a","volume":"41","author":"SI Blaber","year":"2002","unstructured":"Blaber, S. I. et al. Enzymatic properties of rat myelencephalon-specific protease. Biochemistry 41 (4), 1165\u20131173 (2002).","journal-title":"Biochemistry"},{"issue":"3","key":"29070_CR144","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/glia.24100","volume":"70","author":"H Yoon","year":"2022","unstructured":"Yoon, H. et al. Blocking Kallikrein 6 promotes developmental myelination. Glia 70 (3), 430\u2013450 (2022).","journal-title":"Glia"},{"issue":"2","key":"29070_CR145","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/jnc.12293","volume":"127","author":"H Yoon","year":"2013","unstructured":"Yoon, H. et al. Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity. J. Neurochem. 127 (2), 283\u2013298 (2013).","journal-title":"J. Neurochem"},{"issue":"1","key":"29070_CR146","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13195-018-0336-4","volume":"10","author":"K Patra","year":"2018","unstructured":"Patra, K. et al. Assessment of Kallikrein 6 as a cross-sectional and longitudinal biomarker for alzheimer\u2019s disease. Alzheimers Res. Ther. 10 (1), 9 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"29070_CR147","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40035-019-0168-6","volume":"8","author":"O Goldhardt","year":"2019","unstructured":"Goldhardt, O. et al. Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with alzheimer\u2019s disease and associated with CSF-TAU and FDG-PET. Transl Neurodegener. 8, 25 (2019).","journal-title":"Transl Neurodegener"},{"issue":"8","key":"29070_CR148","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0009-9120(00)00185-5","volume":"33","author":"EP Diamandis","year":"2000","unstructured":"Diamandis, E. P. et al. Human Kallikrein 6 as a biomarker of alzheimer\u2019s disease. Clin. Biochem. 33 (8), 663\u2013667 (2000).","journal-title":"Clin. Biochem."},{"issue":"11","key":"29070_CR149","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1212\/WNL.0b013e31822e5627","volume":"77","author":"AR Paciorkowski","year":"2011","unstructured":"Paciorkowski, A. R. et al. Massive expansion of SCA2 with autonomic dysfunction, retinitis pigmentosa, and infantile spasms. Neurology 77 (11), 1055\u20131060 (2011).","journal-title":"Neurology"},{"issue":"3","key":"29070_CR150","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/ane.13359","volume":"143","author":"A Stezin","year":"2021","unstructured":"Stezin, A. et al. In vivo microstructural white matter changes in early spinocerebellar ataxia 2. Acta Neurol. Scand. 143 (3), 326\u2013332 (2021).","journal-title":"Acta Neurol. Scand."},{"issue":"4","key":"29070_CR151","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/jnc.15987","volume":"167","author":"XW Pang","year":"2023","unstructured":"Pang, X. W. et al. Trem2 deficiency attenuates microglial phagocytosis and autophagic-lysosomal activation in white matter hypoperfusion. J. Neurochem. 167 (4), 489\u2013504 (2023).","journal-title":"J. Neurochem"},{"issue":"4","key":"29070_CR152","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1080\/15548627.2022.2117893","volume":"19","author":"J Pan","year":"2023","unstructured":"Pan, J. et al. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. Autophagy 19 (4), 1184\u20131198 (2023).","journal-title":"Autophagy"},{"issue":"29","key":"29070_CR153","doi-asserted-by":"publisher","first-page":"22576","DOI":"10.1074\/jbc.M110.118976","volume":"285","author":"A Jain","year":"2010","unstructured":"Jain, A. et al. p62\/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J. Biol. Chem. 285 (29), 22576\u201322591 (2010).","journal-title":"J. Biol. Chem."},{"key":"29070_CR154","doi-asserted-by":"publisher","first-page":"516746","DOI":"10.3389\/fonc.2020.516746","volume":"10","author":"M Fei","year":"2020","unstructured":"Fei, M. et al. Inhibition of cathepsin S induces mitochondrial apoptosis in glioblastoma cell lines through mitochondrial stress and autophagosome accumulation. Front. Oncol. 10, 516746 (2020).","journal-title":"Front. Oncol."},{"issue":"10","key":"29070_CR155","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1080\/15548627.2015.1083666","volume":"11","author":"JP Decuypere","year":"2015","unstructured":"Decuypere, J. P., Parys, J. B. & Bultynck, G. ITPRs\/inositol 1,4,5-trisphosphate receptors in autophagy: from enemy to ally. Autophagy 11 (10), 1944\u20131948 (2015).","journal-title":"Autophagy"},{"key":"29070_CR156","doi-asserted-by":"crossref","unstructured":"Schultheis, N., Jiang, M. & Selleck, S. B. Putting the brakes on autophagy: the role of Heparan sulfate modified proteins in the balance of anabolic and catabolic pathways and intracellular quality control. Matrix Biol., 100\u2013101 : pp. 173\u2013181. (2021).","DOI":"10.1016\/j.matbio.2021.01.006"},{"issue":"9","key":"29070_CR157","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1158\/1078-0432.CCR-18-1474","volume":"25","author":"WT Wang","year":"2019","unstructured":"Wang, W. T. et al. Activation of the Lysosome-Associated membrane protein LAMP5 by DOT1L serves as a bodyguard for MLL fusion oncoproteins to evade degradation in leukemia. Clin. Cancer Res. 25 (9), 2795\u20132808 (2019).","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"29070_CR158","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.devcel.2016.04.014","volume":"37","author":"W Du","year":"2016","unstructured":"Du, W. et al. Kinesin 1 drives autolysosome tubulation. Dev. Cell. 37 (4), 326\u2013336 (2016).","journal-title":"Dev. Cell."},{"issue":"5\u20136","key":"29070_CR159","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cytogfr.2007.06.003","volume":"18","author":"AG Hovanessian","year":"2007","unstructured":"Hovanessian, A. G. On the discovery of interferon-inducible, double-stranded RNA activated enzymes: the 2\u2019-5\u2019oligoadenylate synthetases and the protein kinase PKR. Cytokine Growth Factor. Rev. 18 (5\u20136), 351\u2013361 (2007).","journal-title":"Cytokine Growth Factor. Rev."},{"issue":"6","key":"29070_CR160","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.molcel.2018.07.029","volume":"71","author":"Y Kim","year":"2018","unstructured":"Kim, Y. et al. PKR senses nuclear and mitochondrial signals by interacting with endogenous Double-Stranded RNAs. Mol. Cell. 71 (6), 1051\u20131063 (2018). .e6.","journal-title":"Mol. Cell."},{"key":"29070_CR161","doi-asserted-by":"crossref","unstructured":"Costa-Mattioli, M. & Walter, P. The integrated stress response: from mechanism to disease. Science, 368(6489). (2020).","DOI":"10.1126\/science.aat5314"},{"key":"29070_CR162","doi-asserted-by":"crossref","unstructured":"Hansen, M. et al. The RNA-Binding protein ATXN2 is expressed during megakaryopoiesis and May control timing of gene expression. Int. J. Mol. Sci., 21(3). (2020).","DOI":"10.3390\/ijms21030967"},{"issue":"1","key":"29070_CR163","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1021\/pr500894v","volume":"14","author":"I Gielisch","year":"2015","unstructured":"Gielisch, I. & Meierhofer, D. Metabolome and proteome profiling of complex I deficiency induced by rotenone. J. Proteome Res. 14 (1), 224\u2013235 (2015).","journal-title":"J. Proteome Res."},{"issue":"4","key":"29070_CR164","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta delta C(T)) method. Methods 25 (4), 402\u2013408 (2001).","journal-title":"Methods"},{"issue":"11","key":"29070_CR165","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-H\u00fcbsch","year":"2006","unstructured":"Schmitz-H\u00fcbsch, T. et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66 (11), 1717\u20131720 (2006).","journal-title":"Neurology"},{"issue":"3","key":"29070_CR166","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s12311-012-0421-3","volume":"12","author":"H Jacobi","year":"2013","unstructured":"Jacobi, H. et al. Inventory of Non-Ataxia signs (INAS): validation of a new clinical assessment instrument. Cerebellum 12 (3), 418\u2013428 (2013).","journal-title":"Cerebellum"},{"issue":"D1","key":"29070_CR167","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47 (D1), D607\u2013d613 (2019).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"29070_CR168","doi-asserted-by":"publisher","first-page":"D433","DOI":"10.1093\/nar\/gky1159","volume":"47","author":"PV Hornbeck","year":"2019","unstructured":"Hornbeck, P. V. et al. 15 years of PhosphoSitePlus\u00ae: integrating post-translationally modified sites, disease variants and isoforms. Nucleic Acids Res. 47 (D1), D433\u2013d441 (2019).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29070-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29070-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29070-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:07:20Z","timestamp":1764324440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29070-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":168,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["29070"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29070-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42559"}}